Overview

AtheroChem is developing technologies to manage and treat atherosclerosis, the cause of coronary artery disease.

AtheroChem is developing agents that directly act on atherosclerotic plaque, and is also developing a complimentary platform assay to assist in determining individual risk profiles for coronary artery disease.

AtheroChem’s research and development technologies are:

ChemStent™ – This program leverages years of basic scientific knowledge in atherosclerosis and cholesterol metabolism.

MIVA™ Platform – This technology builds upon AtheroChem’s internal research assays which focus on the process of macrophage foam cell cholesterol efflux.